Key statistics
On Friday, Corcept Therapeutics Inc (HTD:FRA) closed at 37.93, -0.32% below its 52-week high of 38.05, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.17 |
---|---|
High | 37.93 |
Low | 36.17 |
Bid | 37.66 |
Offer | 38.07 |
Previous close | 38.05 |
Average volume | 207.50 |
---|---|
Shares outstanding | 104.49m |
Free float | 92.42m |
P/E (TTM) | 37.16 |
Market cap | 4.41bn USD |
EPS (TTM) | 1.14 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 20:39 BST.
More ▼
Announcements
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
- Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
- Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
More ▼